Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Noel Barrett

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|May 17, 2017
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled StudyJean-Marc Steens, Didier Scherrer, Paul Gineste, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male SubjectsDidier Scherrer, Regine Rouzier, Marine Cardona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2011
A new approach to a Lyme disease vaccineIan Livey, Maria O'Rourke, Andreas Traweger, et al.
Human Vaccines & Immunotherapeutics|June 16, 2012
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® JuniorRoman Prymula, Eva Maria Pöllabauer, Borislava G Pavlova, et al.
Vaccine|May 11, 2010
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccineEva Maria Pöllabauer, Sandor Fritsch, Borislava G Pavlova, et al.
Plos One|September 21, 2011
Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverBirgit Schäfer, Georg W Holzer, Alexandra Joachimsthaler, et al.
Vaccine|December 19, 2009
Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccinationAndré van Maurik, Nicolas Sabarth, Helga Savidis Dacho, et al.
Journal of Virus Eradication|February 26, 2019
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled studySofie Rutsaert, Jean-Marc Steens, Paul Gineste, et al.
Transfusion|February 21, 2012
Chikungunya virus and the safety of plasma productsSandra M Leydold, Maria R Farcet, Johanna Kindermann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2012
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individualsHartmut J Ehrlich, Julia Singer, Gregory Berezuk, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|May 17, 2017
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled StudyJean-Marc Steens, Didier Scherrer, Paul Gineste, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male SubjectsDidier Scherrer, Regine Rouzier, Marine Cardona, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2011
A new approach to a Lyme disease vaccineIan Livey, Maria O'Rourke, Andreas Traweger, et al.
Human Vaccines & Immunotherapeutics|June 16, 2012
Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® JuniorRoman Prymula, Eva Maria Pöllabauer, Borislava G Pavlova, et al.
Vaccine|May 11, 2010
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccineEva Maria Pöllabauer, Sandor Fritsch, Borislava G Pavlova, et al.
Plos One|September 21, 2011
Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverBirgit Schäfer, Georg W Holzer, Alexandra Joachimsthaler, et al.
Vaccine|December 19, 2009
Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccinationAndré van Maurik, Nicolas Sabarth, Helga Savidis Dacho, et al.
Journal of Virus Eradication|February 26, 2019
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled studySofie Rutsaert, Jean-Marc Steens, Paul Gineste, et al.
Transfusion|February 21, 2012
Chikungunya virus and the safety of plasma productsSandra M Leydold, Maria R Farcet, Johanna Kindermann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2012
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individualsHartmut J Ehrlich, Julia Singer, Gregory Berezuk, et al.
Pageof 7